~~<i id='4B2E1B30FD'><strike id='4B2E1B30FD'><tt id='4B2E1B30FD'><pre id='4B2E1B30FD'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：focus 2025-09-29 08:42:45 Page View：22758

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Senators push IRS to launch nonprofit hospital probe
Next article： Apple is now the first public company to be valued at $3 trillion

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Bird flu researchers hone in on Finland’s mink farms

MinkslookoutfromacageatafurfarminBelarus.SergeiGrits/APHELSINKI—ItwasthequietthatstoodouttoTarjaSiro

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Be careful with at

AdobeHypertensionisconsideredtobetheNo.1riskfactorfordeathglobally.Soit’snowonderconvenient,relative